[8-K] Cardiff Oncology, Inc. Reports Material Event

Rhea-AI Filing Summary

Cardiff Oncology (CRDF) filed an 8-K stating it issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. The press release was furnished as Exhibit 99.1.

The company’s common stock trades on The Nasdaq Stock Market under the symbol CRDF. The report was signed by Chief Executive Officer Mark Erlander on November 6, 2025.

0001213037false00012130372025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Cardiff Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35558	27-2004382
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
11055 Flintkote Avenue
San Diego, California				92121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-7570

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		CRDF		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Cardiff Oncology, Inc. (the "Company") issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release of Cardiff Oncology, Inc. dated November 6, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CARDIFF ONCOLOGY, INC.
Date:	November 6, 2025	By:	/s/ Mark Erlander
			Mark Erlander Chief Executive Officer

FAQ

What did Cardiff Oncology (CRDF) announce in this 8-K?

It reported that a press release with company highlights and financial results for the third quarter ended September 30, 2025 was issued and furnished as Exhibit 99.1.

Which period does the CRDF update cover?

The update covers the third quarter ended September 30, 2025.

Where can I find the detailed Q3 2025 results for CRDF?

Details are in the press release furnished as Exhibit 99.1 to the 8-K.

What is the form type of this Cardiff Oncology filing?

It is a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

What is Cardiff Oncology’s trading symbol and exchange?

The common stock trades under CRDF on The Nasdaq Stock Market LLC.

Who signed the report and on what date?

It was signed by Mark Erlander, Chief Executive Officer, on November 6, 2025.